ETRADE Capital Management LLC Boosts Stake in Eli Lilly and Company (LLY)
ETRADE Capital Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 18,748 shares of the company’s stock after acquiring an additional 2,138 shares during the quarter. ETRADE Capital Management LLC’s holdings in Eli Lilly and were worth $1,543,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Eli Lilly and by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after acquiring an additional 1,610,885 shares during the period. D.A. Davidson & CO. lifted its holdings in Eli Lilly and by 1.2% during the 2nd quarter. D.A. Davidson & CO. now owns 35,908 shares of the company’s stock worth $2,955,000 after purchasing an additional 411 shares in the last quarter. Pinebridge Investments L.P. purchased a new stake in Eli Lilly and during the 2nd quarter worth about $7,402,000. Van ECK Associates Corp lifted its holdings in Eli Lilly and by 1.0% during the 2nd quarter. Van ECK Associates Corp now owns 525,029 shares of the company’s stock worth $43,210,000 after purchasing an additional 5,190 shares in the last quarter. Finally, Quantitative Investment Management LLC lifted its holdings in Eli Lilly and by 12.9% during the 2nd quarter. Quantitative Investment Management LLC now owns 75,200 shares of the company’s stock worth $6,188,000 after purchasing an additional 8,600 shares in the last quarter. Institutional investors own 75.48% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) opened at $83.29 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $91,710.21, a PE ratio of 20.36, a PEG ratio of 1.83 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $64.18 and a 1 year high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company’s revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.88 EPS. sell-side analysts anticipate that Eli Lilly and Company will post 4.22 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.
In other news, major shareholder Lilly Endowment Inc sold 190,000 shares of the stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the transaction, the insider now directly owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 770,000 shares of company stock worth $64,669,850 over the last quarter. Corporate insiders own 0.20% of the company’s stock.
A number of analysts recently issued reports on LLY shares. UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 price objective on the stock. in a report on Wednesday, July 26th. BMO Capital Markets reissued a “sell” rating and set a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies reissued a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Friday, October 13th. Finally, Berenberg Bank reissued a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $89.76.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.